Back to today’s briefing

Story perspectives

Long COVID Hope: Paxlovid Shows Promise, Caution Advised

1/16/2025

47 10

Summary

Story summary

Long COVID patients may find hope in an extended course of Paxlovid, with some reporting temporary or lasting improvements. Yet, experts urge caution as results vary, emphasizing the need for more research. Alarmingly, a study reveals that 4.5% of COVID-19 survivors develop myalgic encephalomyelitis/chronic fatigue syndrome, underscoring the urgent demand for effective treatments.

1 of 1

Story summary

Long COVID patients may find hope in an extended course of Paxlovid, with some reporting temporary or lasting improvements. Yet, experts urge caution as results vary, emphasizing the need for more research. Alarmingly, a study reveals that 4.5% of COVID-19 survivors develop myalgic encephalomyelitis/chronic fatigue syndrome, underscoring the urgent demand for effective treatments.